Press release
Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Polymyositis Pipeline Insight 2024" report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Polymyositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Explore our latest breakthroughs in Polymyositis Research. Learn more about our innovative pipeline today! @ Polymyositis Pipeline Outlook- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Polymyositis Pipeline Report
• In November 2024:- AstraZeneca- The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) [polymyositis (PM) or dermatomyositis (DM)] while receiving standard of care (SoC) treatment.
• In November 2024:- Pfizer- The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM.
• In November 2024:- Priovant Therapeutics Inc.- This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.
• DelveInsight's Polymyositis pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Polymyositis treatment.
• The leading Polymyositis Companies such as Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem LLC., Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others.
• Promising Polymyositis Therapies such as Dazukibart, M5049 high dose, Froniglutide, PF-06823859, EFG PH20 SC, Daxdilimab, and others.
Stay informed about the cutting-edge advancements in Polymyositis treatments. Download for updates and be a part of the revolution in care @ Polymyositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Polymyositis Emerging Drugs Profile
• Ustekinumab: Janssen Pharmaceutical
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin (IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. Currently, it is in Phase III stage of clinical trial evaluation to treat Polymyositis.
• PN-101: PAEAN Biotechnology
PN-101 the world's first allogeneic mitochondrial drug candidate for the treatment of polymyositis and dermatomyositis. PN-101 is the first-in-class drug where the main component consists of mitochondria isolated from stem cells. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Polymyositis.
Learn more about Polymyositis Drugs opportunities in our groundbreaking Polymyositis Research and development projects @ Polymyositis Unmet Needs- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Polymyositis Companies
Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem LLC., Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others
Polymyositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Polymyositis Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Discover the latest advancements in Polymyositis treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Polymyositis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Polymyositis Pipeline Report
• Coverage- Global
• Polymyositis Companies- Janssen Pharmaceutical, PAEAN Biotechnology, Kezar Life Sciences, Roche, Restem LLC., Viela Bio, Bristol-Myers Squibb, ImmunoForge, and others.
• Polymyositis Therapies- Dazukibart, M5049 high dose, Froniglutide, PF-06823859, EFG PH20 SC, Daxdilimab, and others.
• Polymyositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Polymyositis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Polymyositis Pipeline on our website @ Polymyositis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/polymyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Polymyositis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Polymyositis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Ustekinumab: Janssen Pharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. PN-101: PAEAN Biotechnology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Polymyositis Key Companies
21. Polymyositis Key Products
22. Polymyositis- Unmet Needs
23. Polymyositis- Market Drivers and Barriers
24. Polymyositis- Future Perspectives and Conclusion
25. Polymyositis Analyst Views
26. Polymyositis Key Companies
27. Appendix
List of Top Selling Market Research Reports in 2024
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polymyositis Pipeline Therapeutics Assessment Report 2024 (Updated) here
News-ID: 3761075 • Views: …
More Releases from DelveInsight Business Research LLP

Prostate Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Prostate Cancer Pipeline constitutes 80+ key companies continuously working towards developing 80+ Prostate Cancer treatment therapies, analyzes DelveInsight.
Prostate Cancer Overview:
Prostate cancer occurs when cells in the prostate gland begin to grow uncontrollably. The prostate, which is unique to males, produces some of the fluid found in semen. The primary cause of prostate cancer is changes in DNA, which are triggered by mutations. It is usually diagnosed once the cancer has…

Psoriasis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessme …
Psoriasis Pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analyzes DelveInsight.
Psoriasis Overview:
Psoriasis is a chronic inflammatory skin condition that presents with various clinical symptoms and is caused by a combination of genetic, environmental, and immune system factors. It is a non-contagious skin disorder that affects nearly 2% of the global population. The extent of skin involvement can vary from person to person, with cases ranging…

Brain Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Asses …
Brain Cancer Pipeline constitutes 10+ key companies continuously working towards developing 10+ Brain Cancer treatment therapies, analyzes DelveInsight.
Brain Cancer Overview:
Brain metastases occur in 10-16% of patients with metastatic breast cancer and are typically linked to a poor prognosis. The risk of developing brain metastases is higher in younger patients, and in those with estrogen receptor-negative tumors, Her-2+ tumors, or basal-like tumors. Diagnosis is usually made through brain MRI (magnetic resonance…

Gorlin Syndrome Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Gorlin Syndrome Pipeline constitutes 5+ key companies continuously working towards developing 5+ Gorlin Syndrome treatment therapies, analyzes DelveInsight.
Gorlin Syndrome Overview:
Gorlin syndrome is a rare inherited condition that impacts multiple organs and tissues in the body. Individuals with this disorder have a significantly increased risk of developing basal cell skin cancer during adolescence or early adulthood, as well as an elevated risk of medulloblastoma (a type of brain cancer) and other…
More Releases for Polymyositis
Polymyositis Market Size, Share, Region & Country Revenue Analysis & Forecast Ti …
Reports and Data has recently published a new report on the Global Polymyositis Market that offers key insights into the current and emerging trends, key companies and market size and market share on a global and regional level. Despite weak development in Western economies as a whole, M&A (mergers and acquisitions) activity in the healthcare sector has increased dramatically. Not only is there a strong growth in pharmaceutical companies,…
Idiopathic Inflammatory Myopathy Treatment Market Worth $930.6 Million by 2026; …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights™ published this information in an upcoming report, titled, “Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…
Polymyositis Treatment Market Technology, Recent Trends, Demand, Future Growth, …
The Global Polymyositis Treatment Market 2022, which focuses on the Polymyositis Treatment market, evaluates the key components using a top to bottom methodology and allows the client to survey the drawn-out based interest while also forecasting explicit executions. This research conducts an in-depth investigation, clarifies item scope, and expands on industry experiences and perspectives until 2028. The Global Polymyositis Treatment market is a crucial source of information for important and…
Polymyositis Treatment Market Is Projected To Witness Vigorous Expansion By 2026 …
Data Bridge Market Research has recently added a concise research on the Polymyositis Treatment Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological…
Idiopathic Inflammatory Myopathy Treatment Market 2020: Global Share, Industry O …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights(TM) published this information in an upcoming report, titled, "Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…
Idiopathic Inflammatory Myopathy Treatment Market 2020 Global Growth Factor, Siz …
The global idiopathic inflammatory myopathy treatment market size is projected to reach USD 930.6 million by 2026, thereby exhibiting a CAGR of 4.6% during the forecast period. However, the market was worth USD 652.3 million in 2018. Fortune Business Insights(TM) published this information in an upcoming report, titled, "Idiopathic Inflammatory Myopathy Treatment Market Size, Share & Industry Analysis, By Disease Type (Dermatomyositis (DM), Polymyositis (PM), Inclusion Body Myositis (IBM), Necrotizing…